![](https://www.lachmanconsultants.com/wp-content/themes/lac/wp-content/uploads/2023/02/missing-thumbnail.jpg)
Woodcock, Cook and Yu Provide Views of CDER/GDUFA Implementation Movement
In a presentation to the Generic Pharmaceutical Association Fall Technical Workshop today, Dr. Janet Woodcock, Director, Center of Drug Evaluation and Research (CDER), told the audience that the new CDER quality initiatives under GDUFA are designed to have an Integrated team review to Chemistry Manufacturing and Controls, microbiology, dissolution and inspections through the new Office of Pharmaceutical Quality. The inclusion of dissolution review appears to remove that assessment from the bioequivalence review within the Office of Generic Drugs’ (OGD) team.